目的:探讨老年慢性阻塞性肺疾病(chronic obstructive pulmonary disease,COPD)患者中血浆N-端脑钠肽前体(N-terminal pro-brain natriuretic peptide, NT-proBNP) 与肺动脉高压的关系。方法:将99例老年COPD 患者,根据心脏彩超分为单纯COPD 组和COPD 伴轻、中、重度肺动脉高压组,用电化学发光免疫分析法测定血浆NT-ProBNP。结果:COPD合并轻度肺动脉高压的NT-ProBNP 水平较单纯COPD 患者明显升高。并且,随着肺动脉高压程度的增加,NT-ProBNP逐步增高;NT-ProBNP 与肺动脉压呈正相关。随着肺动脉压力的升高,患者临床不良事件发生率亦显著增加。结论:老年COPD患者血浆NT-ProBNP 浓度与肺动脉高压可能关系密切。

Objective To determine the correlation between pulmonary artery hypertension and N-terminal pro-brain natriuretic peptide (NT-proBNP) in elderly patients with chronic obstructive pulmonary disease (COPD).Methods A total of 99 elderly COPD patients were selected and divided into the COPD group and the COPD with pulmonary artery hypertension group in 3 grades. Serum NT-ProBNP was measured by using electrochemiluminescence Immunoassay. Results Level of serum NT-ProBNP in the COPD group with pulmonary artery hypertension was higher than that in the COPD group(P＜0.01).Levels of serum NT-ProBNP increased significantly with the increase in grades of pulmonary artery hypertension. NT-ProBNP was positively correlated with pulmonary arterial pressure. The clinical harmful events of patients increased significantly with the increase in pulmonary artery pressure.Conclusion NT-ProBNP may be closely related to the grade of pulmonary artery hypertension in elderly COPD patients.

[1] Brusselle GG, Joos GF, Bracke KR. New insights into the immunology of chronic obstructive pulmonary disease［J］. Lancet, 2011,378(9795):1015-1026.

[2] Zakynthinos E, Daniil Z, Papanikolaou J, et al. Pulmonary hypertension in COPD: pathophysiology and therapeutic targets［J］. Curr Drug Targets, 2011,12(4):501-513.

[3] Giusca S, Jinga M, Jurcut C, et al. Portopulmonary hypertension: From diagnosis to treatment［J］. Eur J Intern Med, 2011,22(5):441-447.

[4] Kirson NY, Birnbaum HG, Ivanova JI, et al. Excess costs associated with patients with pulmonary arterial hypertension in a US privately insured population ［J］. Appl Health Econ Health Policy, 2011,9(5):293-303.

[5] Souza R, Bogossian HB, Humbert M, et al. N-terminal-pro-brain natriuretic peptide as a haemodynamic marker in idiopathic pulmonary arterial hypertension［J］. Eur Respir J,2005,25(3):509-513.

[6] Toshner MR, Gopalan D, Suntharalingam J, et al. Pulmonary arterial size and response to sildenafil in chronic thromboembolic pulmonary hypertension［J］. J Heart Lung Transplant,2010,29(6):610-615.

[7] Mauritz GJ, Rizopoulos D, Groepenhoff H, et al. Usefulness of serial N-terminal pro-B-type natriuretic peptide measurements for determining prognosis in patients with pulmonary arterial hypertension［J］. Am J Cardiol,2011, .

[8] Jaffe AS, Babuin L, Apple FS. Biomarkers in acute cardiac disease: the present and the future［J］. J Am Coll Cardiol,2006,48(1):1-11.

[9] 中华医学会呼吸病学分会慢性阻塞性肺疾病学组. 慢性阻塞性肺疾病诊治指南［J］.中华内科杂志, 2007, 3(46):254-261. Group of Chronic Obstructive Pulmonary Disease, Committee of Respiratory Disease, Chinese Medical Association. Guideline for Diagnosis and Treatment of Chronic Obstructive Pulmonary Disease［J］. Chinese Journal of Internal Medicine, 2007, 3(46):254-261.

[10] Martinez-Rumayor A, Richards AM, Burnett JC, et al. Biology of the natriuretic peptides［J］. Am J Cardiol, 2008,101(3A):3-8.

[11] de Winter RJ, Stroobants A, Koch KT, et al. Plasma N-terminal pro-B-type natriuretic peptide for prediction of death or nonfatal myocardial infarction following percutaneous coronary intervention［J］. Am J Cardiol, 2004, 94(12):1481-1485.

[12] Karthikeyan G, Moncur RA, Levine O, et al. Is a pre-operative brain natriuretic peptide or N-terminal pro-B-type natriuretic peptide measurement an independent predictor of adverse cardiovascular outcomes within 30 days of noncardiac surgery? A systematic review and meta-analysis of observational studies［J］. J Am Coll Cardiol,2009,54(17):1599-1606.

[13] Mehra MR, Maisel A. B-type natriuretic peptide in heart failure: diagnostic, prognostic, and therapeutic use［J］. Crit Pathw Cardiol,2005,4(1):10-20.

[14] Mendes-Ribeiro AC, Mann GE, de Meirelles LR, et al. The role of exercise on L-arginine nitric oxide pathway in chronic heart failure［J］. Open Biochem J, 2009, 3:55-65.

[15] Leuchte HH, Baumgartner RA, Nounou ME, et al. Brain natriuretic peptide is a prognostic parameter in chronic lung disease［J］. Am J Respir Crit Care Med, 2006, 173(7):744-750.

[16] Chhabra SK, Gupta M. Coexistent chronic obstructive pulmonary disease-heart failure: mechanisms, diagnostic and therapeutic dilemmas［J］. Indian J Chest Dis Allied Sci, 2010, 52(4):225-238.

[17] Nagaya N, Nishikimi T, Okano Y, et al. Plasma brain natriuretic peptide levels increase in proportion to the extent of right ventricular dysfunction in pulmonary hypertension［J］. J Am Coll Cardiol, 1998, 31(1):202-208.